You think NWBO's MAA submission is crappy? Any verifiable evidence? I suppose you have none.
DCVax is the biggest breakthrough in medicine ever!
How many times have you read the Nature paper? Each time I read it, I can find something interesting.
The longs talk about the significance of Poly-ICLC a lot. IMO, they haven't realized the much more significance of TLR7/8 agonist. See the comparison in the variations of some highly overexpressed tumor antigens pre- and post- DC vaccination between Poly-ICLC and 0.2% Resiquimod gel?
I suppose by now you have figured it out that 0.2% Resiquimod gel means the concentration of TLR7/8 agonist is 0.2%. In the trial, 0.2% Resiquimod gel was applied to the DC injection site post DC injection to activates TLR7/8 to enhance T-cell responses and TH1-type cytokine secretion by DCs. Can you imagine what kind of efficacy improvement can be expected if TLR7/8 agonist is administered intravenously? That's why TeLuRide-005, a TLR7/8 agonist from Eikon Therapeutics is so important. The trial results on TeLuRide-005 are without doubt blockbuster. The more interesting part is how Merck owns the global license right on TLR7/8 agonist originally developed by Seven and Eight Biopharma. Right now the global license is owned by Eikon which will be merged with Merck sooner or later. That's why I say Merck owns the license.
I used to think that Roger Perlmutter was forced to retire early because he made Merck miss the opportunity of becoming the first trillion-dollar company. Now I am thinking he joined Eikon Therapeutics because Merck tasked him with a special commission: Getting TLR7/8 agonist ready. Merck has TLR4 agonist, TLR7/8 agonist, BCG, PCV21, PD1 inhibitor and many others complementary ingredients. It seems like Merck has leverage in bargaining with LP. The reality is with Decoy20, Merck has no leverage at all. Again which hedge fund is the largest institutional shareholder of INDP?
Did David Innes once say that the significance of Dr. Bosch's NYAS presentation was underestimated? I would say that the significance of Yorkville's providing $NWBO with three loans this year is completely underestimated. It should be one of the most bullish signs that the board should keep talking. Now go through all the biotech investments by Yorkville this year again and tell me whether I am delusional by saying I have a foretaste of generational wealth.
6-16-2025 Aptevo Therapeutics Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “Purchase Agreement”) with YA II PN, LTD https://cbonds.com/news/3453219/
Market Data 
Markets 
AI
